Page last updated: 2024-11-05

thonzylamine and Esophageal Squamous Cell Carcinoma

thonzylamine has been researched along with Esophageal Squamous Cell Carcinoma in 1 studies

thonzylamine: major descriptor (72-84); file-maintained to PYRIMIDINES

Esophageal Squamous Cell Carcinoma: A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Kobayashi, K1
Kanetaka, K1
Yoneda, A1
Kobayashi, S1
Maruya, Y1
Isagawa, Y1
Yoshimoto, T1
Migita, K1
Kawaguchi, Y1
Kuba, S1
Morita, M1
Okada, S1
Kosaka, T1
Yamaguchi, S1
Inoue, Y1
Adachi, T1
Hidaka, M1
Torashima, Y1
Ito, S1
Takatsuki, M1
Eguchi, S1

Other Studies

1 other study available for thonzylamine and Esophageal Squamous Cell Carcinoma

ArticleYear
Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience.
    Journal of gastrointestinal cancer, 2021, Volume: 52, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; D

2021